June 24, 2021 12:49 PM EDTUpdated 02:01 PM
Manufacturing

J&J, Leg­end un­veil plans for Bel­gian cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty as the part­ners await ap­proval for lead drug

Josh Sullivan

In a race to get BC­MA CAR-T can­di­dates to mar­ket, J&J and Leg­end are adding a new EU man­u­fac­tur­ing fa­cil­i­ty in Bel­gium to the fold …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

No­var­tis used a PRV to speed Kisqal­i's lat­est in­di­ca­tion, FDA says

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times